作者
Ronald S. Go,Jeffrey L. Winters,Nelson Leung,David Murray,Maria Alice V. Willrich,Roshini S. Abraham,Hatem Amer,William J. Hogan,Ariela L. Marshall,Sanjeev Sethi,Cheryl L. Tran,Dong Chen,Rajiv K. Pruthi,Aneel A. Ashrani,Fernando C. Fervenza,Carl H. Cramer,Vilmarie Rodriguez,Alexandra P. Wolanskyj,Stephan D. Thomé,C. Christopher Hook,Ronald S. Go,Jeffrey L. Winters,Nelson Leung,David Murray,Maria Alice V. Willrich,Roshini S. Abraham,Hatem Amer,William J. Hogan,Ariela L. Marshall,Sanjeev Sethi,Cheryl L. Tran,Dong Chen,Rajiv K. Pruthi,Aneel A. Ashrani,Fernando C. Fervenza,Carl H. Cramer,C. Christopher Hook,Vesna D. Garovic,Jennifer C. Yui,Juliana Perez Botero
摘要
Thrombotic microangiopathies (TMAs) comprise a heterogeneous set of conditions linked by a common histopathologic finding of endothelial damage resulting in microvascular thromboses and potentially serious complications. The typical clinical presentation is microangiopathic hemolytic anemia accompanied by thrombocytopenia with varying degrees of organ ischemia. The differential diagnoses are generally broad, while the workup is frequently complex and can be confusing. This statement represents the joint recommendations from a multidisciplinary team of Mayo Clinic physicians specializing in the management of TMA. It comprises a series of evidence- and consensus-based clinical pathways developed to allow a uniform approach to the spectrum of care including when to suspect TMA, what differential diagnoses to consider, which diagnostic tests to order, and how to provide initial empiric therapy, as well as some guidance on subsequent management.